Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to Meet

August 5, 2016 6:44 AM EDT
Get Alerts REGN Hot Sheet
Price: $362.56 --0%

Rating Summary:
    21 Buy, 17 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 13 | New: 9
Trade REGN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Baird downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Neutral with a price target of $488.00 (from $505.00) following Q2 results.

Analyst Brian Skorney commented, "Regeneron posted an EPS beat in the second quarter, driven by operating expense adjustments. Though Eylea sales growth remains strong, after a thorough model review, we think the consensus EPS expectations over the 2017/18 time frame will be hard to meet without a 15-20% downward revision. Near term, with high expectations for dupilumab and sarilumab sales baked in, a slow Praluent launch, and opex set to increase, we are comfortable moving to the sidelines and lowering our price target to $448."

The firm cut FY 2016 EPS from $11.69 to $11.02 and FY 2017 EPS from $15.13 to $12.83.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $433.40 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Robert W Baird

Add Your Comment